Innovation in peptide development through automated LPPS platform

Cambrex has developed an integrated liquid-phase peptide synthesis platform that reimagines how complex peptide drug are developed and manufactured. As peptide therapeutics experience rapid growth the industry faces mounting pressure to manufacture these molecules more efficiently, more sustainably, and at far greater scale than current solid-phase methods allow.Cambrex's platform addresses this challenge through a seamless end-to-end workflow. Predictive algorithms identify optimal convergent synthetic routes for target peptides. High-throughput crystallization screening capability rapidly pinpoints crystalline intermediates that anchor a robust quality strategy. A purpose-built automated synthesizer then optimizes the process with integrated analytical monitoring, generating manufacturing-ready data packages. Because the chemistry requires no specialized resins, polymeric tags, or dedicated peptide reactors, processes transfer directly to standard batch reactors at Cambrex facilities in the US and Europe at scales up to 16,000 liters.The result is a platform that delivers higher-quality peptide drug substances with significantly reduced environmental impact and dramatically compressed development timelines. By removing the infrastructure constraints, proprietary consumable dependencies, and development bottlenecks that have limited peptide manufacturing to date, Cambrex's LPPS platform opens a practical path to meeting the surging global demand for complex peptide therapeutics.